Compare Oracle Corporation (ORCL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Smith & Nephew plc — how do they compare? Oracle Corporation trades at $162.75 (market cap $468.13B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Oracle Corporation is far larger — about 40.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| ORCL | SNN | |
|---|---|---|
Market Cap | $468.13B | $11.63B |
Sector | Technology | Health |
52-Week High | $328.33 | $38.53 |
52-Week Low | $114.99 | $27.80 |
Enterprise Value | $597.38B | $14.66B |
Dividend Yield | 1.23% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) trades at $161.70, up 1.81% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $57.40B in 2025, with net income margin expanding to 25.37%. The stock is supported by positive AI infrastructure developments and a consensus analyst price target of $243.38, indicating significant upside potential from current levels.
The outlook remains positive driven by AI partnerships and cloud growth, but risks include high valuation multiples and rising capital expenditures. Institutional sentiment is bullish with 65% buy ratings, though legal scrutiny and competitive pressures warrant monitoring for sustained momentum.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
